Sertindol

Из Википедије, слободне енциклопедије
Иди на навигацију Иди на претрагу
Sertindol
Sertindole2DACS.svg
Sertindole3Dan.gif
Klinički podaci
Prodajno imeSerdolect, Serlect
Drugs.comMonografija
Farmakokinetički podaci
Poluvreme eliminacije3 dana
Identifikatori
CAS broj106516-24-9 ДаY
ATC kodN05AE03 (WHO)
PubChemCID 60149
IUPHAR/BPS98
DrugBankDB06144 ДаY
ChemSpider54229 ДаY
KEGGC07567 ДаY
ChEBICHEBI:9122 ДаY
ChEMBLCHEMBL12713 ДаY
Hemijski podaci
FormulaC24H26ClFN4O
Molarna masa440,941

Sertindol je organsko jedinjenje, koje sadrži 24 atoma ugljenika i ima molekulsku masu od 440,941 Da.[1][2][3][4][5][6][7][8][9]

Osobine[уреди]

Osobina Vrednost
Broj akceptora vodonika 2
Broj donora vodonika 1
Broj rotacionih veza 5
Particioni koeficijent[10] (ALogP) 4,7
Rastvorljivost[11] (logS, log(mol/L)) -6,4
Polarna površina[12] (PSA, Å2) 40,5

Reference[уреди]

  1. ^ Kane JM, Tamminga CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs. 1997 Nov;6(11):1729-41. PMID 15989577
  2. ^ Lewis R, Bagnall AM, Leitner M: Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. PMID 16034864
  3. ^ Perquin LN: Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol. 2005 Nov;20(6):335-8. PMID 16192844
  4. ^ Murdoch D, Keating GM: Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55. PMID 16529528
  5. ^ Sertindole: new drug. Another atypical neuroleptic; QT prolongation. Prescrire Int. 2007 Apr;16(88):59-62. PMID 17458045
  6. ^ Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006 Sep;7(13):1825-34. PMID 16925508
  7. ^ Hertel P: Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse. 2006 Dec 1;60(7):543-52. PMID 16952163
  8. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  9. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  10. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  11. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  12. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Literatura[уреди]

Spoljašnje veze[уреди]

Star of life.svgMolimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).